5-Methoxy psoralen, etretinate, and UVA for psoriasis.
This first Australasian randomized trial of 5-methoxy psoralen (5-MOP) PUVA for psoriasis shows, conclusively, less acute side effects than 8-MOP PUVA. Daily addition of oral etretinate to the PUVA regimen (Re-PUVA) produces a valuable reduction in total joules and more so with 5-MOP than with 8-MOP. The clearing phase with 5-MOP Re-PUVA is quicker than with 8-MOP Re-PUVA in skin types 1, 2, and 3 (most Anglo-Saxon-Celtic Australians). Doses, when adapted to total body surface rather than mg/kg, allow superior control of therapy. Emollient creams, tar gels, nonsteroidal scalp applications, etc. allow more patient comfort.
Lane-Brown
M
M
Macquarie Area Health Service, Ryde Hospital, New South Wales, Australia.
D000078223:5-Methoxypsoralen; D000287:Administration, Topical; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000008:administration & dosage*; D006801:Humans; D008730:Methoxsalen / Q000008:administration & dosage*; D011701:PUVA Therapy; D011565:Psoriasis / Q000188:drug therapy*
D000078223:5-Methoxypsoralen; D005050:Etretinate; D008730:Methoxsalen